MRKR Stock Analysis: Buy, Sell, or Hold?
MRKR - Marker Therapeutics, Inc. Common Stock
$1.44
-0.02 (-1.37%)
▼
5d:
-14.29%
30d:
+5.11%
90d:
-17.24%
WAIT
LOW Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 13, 2026
28d
Get Alerted When MRKR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MRKR is down 14.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MRKR is down 14.3% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MRKR is currently trading at $1.44, which is considered fair relative to its 30-day fair value range of $1.34 to $1.52.
Technical Outlook: Technically, MRKR is in a downtrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MRKR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.87 (+446.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MRKR is in a downtrend. The price is currently testing key support at $1.40. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MRKR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.87 (+446.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.34 -
$1.52
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
86.8%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 446.3% below Wall St target ($7.87)
- WARNING: Recommendation downgraded due to -14.3% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.34 -
$1.52
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.40
Resistance Level
$1.59
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.91
Wall Street Target
$7.87
(+446.3%)
Revenue Growth (YoY)
-51.0%
Share & Embed Analysis
Last updated: July 15, 2026 8:06 AM ET
Data refreshes hourly during market hours. Next update: 9:06 AM
Data refreshes hourly during market hours. Next update: 9:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MRKR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 65 BUY |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1051 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 50 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 58 HOLD |
